AzTrials
AzTrials

Patent Foramen OvaleEarly Phase 1NCT03945643

Is Blood Flow Through IPAVA and PFO Related to Breath-hold and SCUBA Diving-induced Pulmonary Hypertension?

A Early Phase 1 study testing Sildenafil in people with Patent Foramen Ovale and Intrapulmonary Arteriovenous Anastamosis, run by University of Oregon at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In summary, the investigators propose to study elite Croatian breath-hold and SCUBA divers. The investigators will quantify breath-hold hypoxia- and SCUBA diving-induced pulmonary hypertension and right heart function to investigate the relationships between PFO and IPAVA blood flow. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
What is being tested?
Sildenafil
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
82 participants
Where
1 siteUnited States
Study dates
1 Jul 2019to 31 Jul 2023
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Reside in geographic location near Split, Croatia
  • Elite breath hold divers
  • Experienced SCUBA divers

Who cannot join

  • Previous history of coronary artery disease
  • Currently taking medication or herbal supplement for any heart or respiratory disease that cannot be ceased for 48 hours prior to testing
  • Women who are pregnant or trying to become pregnant
  • Previous history of any condition that would prevent the subject from performing a breath hold
  • Taking sildenafil or products similar to sildenafil
  • Taking Nitrates or other nitric oxide donors
  • Control breath hold divers can't have previous breath hold diving experience

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Cardiorespiratory and Pulmonary Physiology Lab

    Eugene, Oregon, 97403

Other trials in United States

About this study

In summary, the investigators propose to study elite Croatian breath-hold and SCUBA divers. The investigators will quantify breath-hold hypoxia- and SCUBA diving-induced pulmonary hypertension and right heart function to investigate the relationships between PFO and IPAVA blood flow. The investigators will use a placebo-controlled intervention (sildenafil) to reduce pulmonary arterial pressure in these subjects to examine the impact of the change in pressure (or absence of change) on the relationships determined above.

Read the detailed description

Pulmonary arterial hypertension (increased lung blood pressure) is a multifactorial disease without a cure. Investigating reversible forms of pulmonary hypertension induced under extreme conditions such as a prolonged breath-hold and/or SCUBA diving may help to better understand why some individuals develop this devastating disease, and others do not.

Pulmonary arterial pressure is typically very low in healthy humans. Low oxygen levels (hypoxia) cause a constriction of the lung blood vessels resulting in smaller diameters, but lung blood flow stays constant or increases. Having constant flow with smaller vessel diameters causes pulmonary arterial pressure to increase but it will return to normal once normal oxygen levels are restored. Moreover, there is an association with patent foramen ovale (PFO, small hole between the atria in the heart) and excessive pulmonary arterial pressures in low oxygen conditions. However, the reasons for the exacerbated increase in pulmonary arterial pressure in these subjects with a PFO (PFO+) is unknown, but may be due to an exaggerated constriction response to low oxygen.

During a breath-hold, the oxygen in the lung decreases and in elite breath-hold divers, it decreases to very low levels. Compared to subjects without a PFO (PFO-), the oxygen may drop even lower in those PFO+ subjects because deoxygenated blood travels through the small hole to mix with oxygenated blood, exacerbating the level to which blood oxygen decreases. Thus, using a breath-hold model of lung hypoxia is one approach to examining a hypoxia-induced increase in pulmonary arterial pressure - a method critically dependent upon the elite breath-hold diver's ability to hold their breath for significant durations.

Intrapulmonary arteriovenous anastomoses (IPAVA) are vessels within the lung that bypass capillaries. The investigator's group has investigated the possible roles these unique vessels may have in physiological and pathophysiological conditions. The investigators have found that IPAVA blood flow occurs when healthy subjects breathe low oxygen gas. The investigators have also found that IPAVA blood flow is inversely related to pulmonary arterial pressure. Specifically, individuals with high pulmonary arterial pressures have low IPAVA blood flow and vice versa.

The right ventricle of the heart pumps blood through the pulmonary artery to the lungs. Under resting conditions the right heart performs a minimal amount of work because the pressure in the lung blood vessels is low. When pulmonary arterial pressure increases, the work of the right side of the heart has to increase substantially to keep blood pumping through the lung. Thus, high pulmonary arterial pressures will increase the work of the right heart and may lead to right heart dysfunction thereby limiting the amount of blood the heart can pump. If the pressure is high enough to limit the amount of blood flowing through the lung then this can be detected by a reduction in pulmonary blood flow and/or changes in the function of the heart during contraction (systole) and relaxation (diastole). Accordingly, an intervention that reduces pulmonary arterial pressures during a breath-hold may have a beneficial effect on right heart function.

Taken together, during an elite breath-hold dive, where the level of oxygen decreases, the investigators expect that pulmonary arterial pressures will increase as lung oxygen levels decrease, and the reduction in oxygen may be even lower in PFO+ subjects. Furthermore, as blood oxygen levels decrease, IPAVA blood flow will increase in some PFO- subjects thereby keeping pulmonary arterial pressures low in those individuals. Conversely, PFO+ subjects and those PFO- subjects with low levels of IPAVA blood flow would be expected to have the greatest pulmonary pressures. Whether or not this is true is unknown. Therefore, Objective #1 will quantify pulmonary arterial pressure and right heart function and investigate their relationships with PFO and IPAVA blood flow in elite breath-hold divers while breathing concentrations of oxygen and carbon dioxide that mimic breath-hold-induced hypoxia [NOTE: it is not possible to image the heart during a breath hold because the fully inflated lung obstructs the ultrasound view of the heart]. Objective #2 will use sildenafil, a drug that increases nitric oxide bioavailability to dilate lung blood vessels, to decrease pulmonary arterial pressure while breathing concentrations of oxygen and carbon dioxide that mimic breath-hold-induced hypoxia. Investigators will quantify the effect of sildenafil on pulmonary arterial pressure and right heart function and will determine if it alters the relationship with IPAVA and PFO blood flow. As mentioned above, because those PFO+ subjects may have an exaggerated pulmonary vasoconstrictor response to hypoxia, sildenafil may be either less effective or ineffective in reducing the pulmonary arterial pressure in these subjects. Objective #3 will compare the elite breath hold diver study data to data obtained in age, sex and PFO matched subjects who do not have extensive experience with breath hold diving. To do this control subjects will undergo the same procedures in Objectives #1 \& 2 above. These studies will also allow investigators to determine if there are differences in pulmonary vascular responses to hypoxia between those with and without breath hold diving experience.

In addition to the heart and lung alterations that occur in breath hold divers outlined above, it is also known that pulmonary arterial pressure increases after SCUBA diving, but returns to normal within a few hours. The mechanisms responsible for the increase in pulmonary arterial pressure are unknown, but are independent of hypoxia. Thus, investigating the relationship between IPAVA, PFO and SCUBA diving-induced increases in pulmonary arterial pressures offers an additional avenue for understanding pulmonary arterial hypertension susceptibility. Although it is unknown why pulmonary arterial pressure increases with SCUBA diving, it is known that pulmonary hypertension may contribute to right heart dysfunction and pulmonary edema (lung water accumulation) that can occur in subjects who are swimming and/or SCUBA diving. Prevention of increased pulmonary arterial pressures during and/or after a dive may help to prevent excessive right heart dysfunction and pulmonary edema. Thus, Objective #4 will quantify pulmonary arterial pressure and right heart function and investigate their relationships with PFO and IPAVA blood flow, pre- and post-SCUBA diving. Objective #5 will quantify the effect of sildenafil (post dive) on pulmonary arterial pressure and right heart function and will determine if it alters the relationship with IPAVA and PFO blood flow, pre- and post-SCUBA diving.

In summary, the investigators propose to study elite Croatian breath-hold and SCUBA divers. Investigators will quantify breath-hold hypoxia- and SCUBA diving-induced pulmonary hypertension and right heart function to investigate the relationships between PFO and IPAVA blood flow. Investigators will use a placebo-controlled intervention (sildenafil) to reduce pulmonary arterial pressure in these subjects to examine the impact of the change in pressure (or absence of change) on the relationships determined above.

Being tested
Sildenafil, Placebo
Medical subject headings
Foramen Ovale, Patent

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SildenafilDrug

    50mg administration of sildenafil, one time, one hour prior to measurements.

  • PlaceboOther

    50mg administration in gel-encapsulated microcrystalline cellulose one time, one hour prior to measurements.

Study groups in NCT03945643
Study groupRoleWhat they receive
Sildenafil administrationActive comparatorAdministration of 50mg sildenafil one time, one hour prior to measurements
Receives: Drug: Sildenafil
Placebo administrationPlacebo comparatorAdministration of 50mg placebo one time, one hour prior to measurements
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pulmonary Pressure

    Pulmonary arterial pressure measured by ultrasound techniques

    Measured: 1 hour post intervention

  2. Concentration of Myoglobin

    Inflammatory cytokine

    Measured: 1 hour post intervention

  3. Concentration of MRP8/14

    Inflammatory cytokine

    Measured: 1 hour post intervention

  4. Concentration of NGAL

    Inflammatory cytokine

    Measured: 1 hour post intervention

  5. Concentration Of CRP

    Inflammatory cytokine

    Measured: 1 hour post intervention

  6. Concentration Of MMP-2

    Inflammatory cytokine

    Measured: 1 hour post intervention

  7. Concentration of OPN

    Inflammatory cytokine

    Measured: 1 hour post intervention

  8. Concentration Of SAA

    Inflammatory cytokine

    Measured: 1 hour post intervention

  9. Concentration of IGFBP-4

    Inflammatory cytokine

    Measured: 1 hour post intervention

  10. Concentration of ICAM-1

    Inflammatory cytokine

    Measured: 1 hour post intervention

  11. Concentration of VCAM-1

    Inflammatory cytokine

    Measured: 1 hour post intervention

  12. Concentration of MMP-9

    Inflammatory cytokine

    Measured: 1 hour post intervention

  13. Concentration of Cystatin C

    Inflammatory cytokine

    Measured: 1 hour post intervention

  14. Change in Q-IPAVA

    Minute bloodflow through intrapulmonary arteriovenous anastamoses

    Measured: 1 hour post intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 May 2019
  2. Study start1 Jul 2019
  3. Primary completion31 Jan 2023
  4. Study completion31 Jul 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Model description
Breath hold divers will be administered sildenafil and placebo. Age-matched controls will be administered sildenafil and placebo.
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
82 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03945643
Sponsor's protocol ID
07302018.031
Status last verified
Aug 2023
First submitted
8 May 2019
Last updated
14 Aug 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No: Plan to not share IPD.

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Sildenafil in people with Patent Foramen Ovale and Intrapulmonary Arteriovenous Anastamosis, run by University of Oregon at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pulmonary Pressure (time frame: 1 hour post intervention). The study lists 14 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in